GLP-1 receptor agonists 'have changed the playing field' in pediatric MASLD

WASHINGTON — Glucagon-like peptide-1 receptor agonists significantly reduced alanine aminotransferase levels in pediatric metabolic dysfunction-associated steatotic liver disease, especially those with type 2 diabetes, researchers reported.
“The study was prompted by my interest in the use of anti-obesity medications in the treatment of MASLD,” Jennifer A. Panganiban, MD,

Related Keywords

Philadelphia ,Pennsylvania ,United States ,Washington ,Heather Biele ,Jennifera Panganiban ,Saxenda Victoza ,Byrobert Stott ,Ozempic Wegovy ,Novo Nordisk ,Astrazeneca ,Non Alcoholic Fatty Liver Disease Program ,Pediatric Gastroenterology ,